Resistance to antibiotics: Administrative response to the challenge

Managed Care Interface

Volumn 17, Issue 12, 2004, Pages 20-29

  Marshall, Deborah A ^a   McGeer, Allison J ^b   Jaszewski, Barbara A ^c,f   Grootendorst, Paul V ^d   Green, Karen A ^b   Laframboise, Melanie F ^a   Low, Donald E ^b   MacLeod, Stuart M ^a,e  

^a i3 Global   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c Hlth Econ and Outcomes Research   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Bayer Inc

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM; CEFALEXIN; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; COMMUNITY ACQUIRED PNEUMONIA; COUGHING; DRUG COST; DRUG EFFECT; DRUG RESPONSE; DRUG USE; GOVERNMENT; HEALTH CARE POLICY; HUMAN; NONHUMAN; PATIENT; POPULATION; PRESCRIPTION; REIMBURSEMENT; STREPTOCOCCUS PNEUMONIA; TAX;

DRUG COSTS; DRUG RESISTANCE, MICROBIAL; HUMANS; REIMBURSEMENT MECHANISMS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 11144233718     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Blondeau JM, Vaughan D: A review of antimicrobial resistance in Canada. Can J Microbiol 2000;46:867-877.
2. Conly J: Antimicrobial resistance in Canada. CMAJ 2002;167:885-891.
3. Low DE: Appropriate antibiotic use: Reducing the emergence and dissemination of resistance. Int J Clin Pract 2000;115:106-110.
4. Gould IM: A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 1999;43:459-465.
5. Evans RG: Strained/Mercy: The Economics of Canadian Health Care. Toronoto/Vancouver, Butterworth-Heinemann, 1984.
6. Huttin C: The use of prescription charges. Health Policy 1994;27:53-73.
7. Levy RA: Prescription cost sharing: Economic and health impacts, and implications for health policy. Pharmacoeconomics 1992;2:219-237.
8. Reeder CE, Lingle EW, Schulz RM, et al: Economic impact of cost-containment strategies in third party programmes in the US (Part I). Pharmacoeconomics 1993;4:92-103.
9. Soumerai SB, Ross-Degnan D, Fortess EE, et al: A critical analysis of studies of state drug reimbursement policies: Research in need of discipline. Milbank Q 1993;71:217-252.
10. Tamblyn R, Laprise R, Hanley JA, et al: Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285:421-429.
11. Burke JP: Antibiotic resistance - squeezing the balloon? JAMA 1998;280:1270-1271.
12. Jernigan DB, Cetron MS, Breiman RF: Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). A strategy from the DRSP Working Group. JAMA 1996;275:206-209.
13. Conly J, for the Canadian Committee on Antibiotic Resistance: Antibiotic resistance in Canada and the Canadian Committee on Antibiotic Resistance. Can J Infect Dis 2000;11:3C-23C.
14. Carbon C, Bax RP: Regulating the use of antibiotics in the community. BMJ 1998;317:663-665.
15. Dunagan WC, Medoff G: Formulary control of antimicrobial usage. What price freedom? Diagn Microbiol Infect Dis 1993;16:265-274.
16. Swartz MN: Use of antimicrobial agents and drug resistance. N Engl J Med 1997;337:491-492.
17. White AC Jr, Atmar RL, Wilson J, et al: Effects of requiring prior authorization for selected antimicrobials: Expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997;25:230-239.
18. Seppala H, Klaukka T, Lehtonen R, et al: Outpatient use of erythromycin: Link to increased erythromycin resistance in group A streptococci. Clin Infect Dis 1995;21:1378-1385.
19. Baquero F: Evolving resistance patterns of Streptococcus pneumoniae: A link with long-acting macrolide consumption? J Chemother 1999;11(suppl 1):35-43.
20. Lipsitch M: Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. Clin Infect Dis 2001;32:1044-1054.
21. Health Canada and The Canadian Infectious Disease Society: Controlling Antimicrobial Resistance. An Integrated Action Plan for Canadians. Ottawa, Ontario, Canada Communicable Disease Report No. 23S7, 1997.
22. Seppala H, Klaukka T, Vuopio-Varkila J, et al, for the Finnish Study Group for Antimicrobial Resistance: The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997;337:441-446.
23. Westh H, Jarlov JO, Kjersem H, et al: The disappearance of multiresistant Staphylococcus aureus in Denmark: Changes in strains of the 83A complex between 1969 and 1989. Clin Infect Dis 1992;14:1186-1194.
24. Low DE: Antimicrobial drug use and resistance among respiratory pathogens in the community. Clin Infect Dis 2001;33(suppl 3):206-213.
25. Zhanel GG, Palatnick L, Nichol KA, et al: Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003;47:1867-1874.
26. Gonzales R, Bartlett JG, Besser RE, et al: Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: Background, specific aims, and methods. Ann Intern Med 2001;134:479-486.
27. Emmer CL, Besser RE: Combating antimicrobial resistance: Intervention programs to promote appropriate antibiotic use. Infect Med 2002;19:160-173.
28. McCaig LF, Hughes JM: Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995;273:214-219.
29. Austin DJ, Kristinsson KG, Anderson RM: The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999;96:1152-1156.
30. Schrag SJ, Beall B, Dowell SF: Limiting the spread of resistant pneumococci: Biological and epidemiologic evidence for the effectiveness of alternative interventions. Clin Microbiol Rev 2000;13:588-601.
31. Rafferty T, Wilson-Davis K, McGavock H: How has fundholding in Northern Ireland affected prescribing patterns? A longitudinal study. BMJ 1997;315:166-170.
32. Belongia EA, Sullivan BJ, Chyou P, et al: A community intervention trial to promote judicious antibiotic use and reduce penicillin-resistant Streptococcus pneumoniae carriage in children. Pediatrics 2001;108:575-583.
33. Hennessy TW, Peterson KM, Bruden D, et al: Changes in antibiotic-prescribing practices and carriage of penicillin-resistant Streptococcus pneumoniae: A controlled intervention trial in rural Alaska. Clin Infect Dis 2002;34:1543-1550.
34. Finkelstein JA, Davis RL, Dowell SF, et al: Reducing antibiotic use in children: a randomized trial in 12 practices. Pediatrics 2001;108:1-7.
35. Grimshaw JM, Russell IT: Effect of clinical guidelines on medical practice: A systematic review of rigorous evaluations. Lancet 1993;342:1317-1322.
36. Majumdar SR, Soumerai SB: Why most interventions to improve physician prescribing do not seem to work. CMAJ 2003;169:30-31.
37. Davis DA, Thomson MA, Oxman AD, et al: Changing physician performance. A systematic review of the effect of continuing medical education strategies. JAMA 1995;274:700-705.
38. Wilton P, Smith R, Coast J, et al: Strategies to contain the emergence of antimicrobial resistance: A systematic review of effectiveness and cost-effectiveness. J Health Serv Res Policy 2002;7:111-117.
39. Jacobs MR: Respiratory tract infection: Epidemiology and surveillance. J Chemother 1997;9:10-17.
40. Appelbaum PC: Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin Infect Dis 2002;34:1613-1620.
41. Pneumococcal immunization program introduction: Information for healthcare providers. Manitoba Health, Public Health 2000 (www.gov.mb.ca/health/ publichealth/cdc/fs/Pneumo.pdf).
42. Antibiotic resistance in Canada, Canadian Bacterial Diseases Network.January 2002 (www.ccar-ccra.com/powerpoint/NipaPressConfLowFeb27.ppt).
43. National data for Streptococcus pneumoniae, 2003 Canadian Bacterial Surveillance Network.(www.microbiology.mtsinai.on.ca/data/sp/spnat.html).
44. Doern GV: Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin Infect Dis 2001;33(suppl)187-192.
45. Doern GV, Heilmann KP, Huynh HK, et al: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-1729.
46. Amsden GW, Amankwa K: Pneumococcal resistance: The treatment challenge. Ann Pharmacother 2001;35:480-488.
47. Diekema DJ, Pfaller MA, Schmitz FJ, et al: Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):114-132.
48. Low DE, de Azavedo J, Weiss K, et al: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002;46:1295-1301.
49. de Azavedo JC, Trpeski L, Pong-Porter S, et al: In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada. Antimicrob Agents Chemother 1999;43:2299-2301.
50. Karlowsky JA, Kelly LJ, Thornsberry C, et al: Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002;46:2540-2545.
51. Odland BA, Jones RN, Verhoef J, et al: Antimicrobial activity of gatifloxacin (AM-1155, CG5501) and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Surveillance Group (Americas and Europe). Diagn Microbiol Infect Dis 1999;34:315-320.
52. Blasi F, Tarsia P, Cosentini R, et al: Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections. Expert Opin Investig Drugs 2003;12:1165-1177.
53. Bartlett JG, Dowell SF, Mandell LA, et al, for the Infectious Diseases Society of America: Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-382.
54. Mandell LA, Marrie TJ, Grossman RF, et al, for the Canadian Community-Acquired Pneumonia Working Group: Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421.
55. Salkind AR, Cuddy PG, Foxworth JW: Fluoroquinolone treatment of community-acquired pneumonia: A meta-analysis. Ann Pharmacother 2002;36:1938-1943.
56. Ontario Ministry of Health and Long Term Care. Antibiotic resistance: Antibiotic review and Ontario Drug Benefit formulary listing changes. Drug Quality and Therapeutics Bulletin, February 2001.
57. 2001/02 Report card for Ontario Drug Benefit Program, Ministry of Health and Long-Term Care 2002 (www.health.gov.on.ca/english/public/pub/ministry/ reports/odb.report01/drug/rep/sld001.htm).
58. Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA, National Committee for Clinical Laboratory Standards, 2002.
59. Ostrom CW: Time Series Analysis: Regression Techniques. Newbury Park, CA, Sage, 1990.
60. Greenland S, Rothman KJ: Introduction to categorical statistics, in Rothman KJ, Greenland S (eds): Modern Epidemiology. Ed. 2. Philadelphia, Lippincott-Raven, 1998; 231-252.
61. Kurzer E, Kaplan S: Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. Eur Urol 2002;42:163-166.
62. Beilby J, Marley J, Walker D, et al: Effect of changes in antibiotic prescribing on patient outcomes in a community setting: A natural experiment in Australia. Clin Infect Dis 2002;34:55-64.
63. LeLorier J, Derderian F: Effect of listing ciprofloxacin in provincial formularies on hospitalizations for bronchitis and pyelonephritis. Can J Clin Pharmacol 1998;5:133-137.
64. Chen DK, McGeer A, de Azavedo JC, et al, for the Canadian Bacterial Surveillance Network: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-239.